Genmab A/S Sponsored ADR $GMAB Position Reduced by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd decreased its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 9.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 29,329 shares of the company’s stock after selling 3,147 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Genmab A/S were worth $606,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Headlands Technologies LLC grew its position in Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after buying an additional 1,464 shares during the last quarter. CWM LLC grew its position in Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after buying an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after buying an additional 1,070 shares during the last quarter. Parallel Advisors LLC grew its position in Genmab A/S by 377.5% during the 2nd quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock worth $77,000 after purchasing an additional 2,941 shares in the last quarter. Finally, Brooklyn Investment Group grew its position in Genmab A/S by 729.3% during the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company’s stock worth $83,000 after purchasing an additional 3,734 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on GMAB. HC Wainwright reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price for the company in a research note on Tuesday, September 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Zacks Research lowered shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Finally, Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Price Performance

Genmab A/S stock opened at $29.19 on Thursday. The firm has a market cap of $18.74 billion, a price-to-earnings ratio of 14.67, a P/E/G ratio of 1.59 and a beta of 0.96. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $33.65. The firm has a fifty day moving average price of $29.46 and a two-hundred day moving average price of $24.34.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. As a group, sell-side analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.